Conflict of interest: the second and last author have participated in the REACH study by inclusion of patients (initiated by Centocor). The company did not play any role in the writing of this article.
Antitumor necrosis factor treatment for pediatric inflammatory bowel disease†
Article first published online: 20 SEP 2011
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 5, pages 985–1002, May 2012
How to Cite
de Bie, C. I., Escher, J. C. and de Ridder, L. (2012), Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis, 18: 985–1002. doi: 10.1002/ibd.21871
- Issue published online: 12 APR 2012
- Article first published online: 20 SEP 2011
- Manuscript Accepted: 29 JUL 2011
- Manuscript Received: 12 JUL 2011
- pediatric inflammatory bowel disease;
Infliximab, adalimumab, and certolizumab are monoclonal antibodies against tumor necrosis factor-α (TNFα), a proinflammatory cytokine with an increased expression in the inflamed tissues of inflammatory bowel disease (IBD) patients. Currently, infliximab is the only anti-TNF drug that has been approved for use in refractory pediatric Crohn's disease (CD). Nevertheless, adalimumab and certolizumab have been used off-label to treat refractory pediatric IBD. Over the past 10 years, anti-TNF treatment has been of great benefit to many pediatric IBD patients, but their use is not without risks (infections, autoimmune diseases, malignancies). Despite the growing experience with these drugs in children with IBD, optimal treatment strategies still need to be determined. The purpose of this review is to summarize the current knowledge on the use of anti-TNF drugs in pediatric IBD and to discuss the yet-unsolved issues. (Inflamm Bowel Dis 2011;)